Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer

Detalhes bibliográficos
Autor(a) principal: Cruz-Duarte, Raquel
Data de Publicação: 2022
Outros Autores: de Almeida, Cátia Rebelo, Negrão, Magda, Fernandes, Afonso, Borralho, Paula, Sobral, Daniel, Gallego-Paez, Lina M., Machado, Daniel, Gramaça, João, Vílchez, José, Xavier, Ana T., Ferreira, Miguel Godinho, Miranda, Ana R., Mansinho, Hélder, Brito, Maria J., Pacheco, Teresa R., Abreu, Catarina, Lúcia-Costa, Ana, Mansinho, André, Fior, Rita, Costa, Luís, Martins, Marta
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/151024
Resumo: P. Borralho reports grants from Roche and Novartis, as well as personal fees from Bayer and AstraZeneca outside the submitted work. D. Machado reports personal fees from Amgen and Merck outside the submitted work. H. Mansinho reports grants from AstraZeneca; nonfinancial support from AstraZeneca; and personal fees from Roche, Pfizer, Pierre Fabre, Incyte, BMS, Novartis, Amgen, Servier, Merck Serono, and Grunenthal outside the submitted work. A. Mansinho reports personal fees and nonfinancial support from Merck-Serono during the conduct of the study, as well as personal fees and nonfinancial support from Amgen, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Vifor Pharma, Pfizer, Pierre Fabre, Roche, and Servier outside the submitted work. L. Costa reports grants from Merck-Serono during the conduct of the study. M. Martins reports grants from Liga Portuguesa Contra o Cancro/Terry Fox and Merck-Serono during the conduct of the study. No disclosures were reported by the other authors. We acknowledge the help of Carla Sousa and Genomed for assessing RAS mutations on tumor samples, the help of Dr. Vasco Rodrigues, and Dr. Rui Marques for their contribution at the Hospital Santa Maria Pharmacy and Champalimaud Fish Platform (C. Certal and J. Monteiro) for excellent animal care. We thank Tom Bunney and Matilda Katan for helpful advice on this project and contribution with PLCg1 plasmids. The authors thank Champalimaud Foundation and M. Godinho Ferreira for the initial support of this project. M. Martins’ research was supported by Liga Portuguesa Contra o Cancro (LPCC): Terry Fox Fundation; A. Fernandes was supported by LPCC-IMM BIOBANK; R. Fior was supported by Champalimaud Foundation and L. Costa was supported by Merck Serono. Publisher Copyright: © 2022 The Authors.
id RCAP_772a8452f6240dab57126fc19577ed81
oai_identifier_str oai:run.unl.pt:10362/151024
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal CancerOncologyCancer ResearchSDG 3 - Good Health and Well-beingP. Borralho reports grants from Roche and Novartis, as well as personal fees from Bayer and AstraZeneca outside the submitted work. D. Machado reports personal fees from Amgen and Merck outside the submitted work. H. Mansinho reports grants from AstraZeneca; nonfinancial support from AstraZeneca; and personal fees from Roche, Pfizer, Pierre Fabre, Incyte, BMS, Novartis, Amgen, Servier, Merck Serono, and Grunenthal outside the submitted work. A. Mansinho reports personal fees and nonfinancial support from Merck-Serono during the conduct of the study, as well as personal fees and nonfinancial support from Amgen, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Vifor Pharma, Pfizer, Pierre Fabre, Roche, and Servier outside the submitted work. L. Costa reports grants from Merck-Serono during the conduct of the study. M. Martins reports grants from Liga Portuguesa Contra o Cancro/Terry Fox and Merck-Serono during the conduct of the study. No disclosures were reported by the other authors. We acknowledge the help of Carla Sousa and Genomed for assessing RAS mutations on tumor samples, the help of Dr. Vasco Rodrigues, and Dr. Rui Marques for their contribution at the Hospital Santa Maria Pharmacy and Champalimaud Fish Platform (C. Certal and J. Monteiro) for excellent animal care. We thank Tom Bunney and Matilda Katan for helpful advice on this project and contribution with PLCg1 plasmids. The authors thank Champalimaud Foundation and M. Godinho Ferreira for the initial support of this project. M. Martins’ research was supported by Liga Portuguesa Contra o Cancro (LPCC): Terry Fox Fundation; A. Fernandes was supported by LPCC-IMM BIOBANK; R. Fior was supported by Champalimaud Foundation and L. Costa was supported by Merck Serono. Publisher Copyright: © 2022 The Authors.Purpose: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To increase cetuximab efficacy, it is crucial to successfully identify responder patients, as well as to develop new therapeutic approaches to overcome cetuximab resistance. Experimental Design: We evaluated the value of EGFR effector phospholipase C gamma 1 (PLCγ1) in predicting cetuximab responses, by analyzing progression-free survival (PFS) of a multicentric retrospective cohort of 94 treated patients with mCRC (logrank test and Cox regression model). Furthermore, we used in vitro and zebrafish xenotransplant models to identify and target the mechanism behind PLCγ1-mediated resistance to cetuximab. Results: In this study, levels of PLCγ1 were found increased in RAS WT tumors and were able to predict cetuximab responses in clinical samples and in vitro and in vivo models. Mechanistically, PLCγ1 expression was found to bypass cetuximab-dependent EGFR inhibition by activating ERK and AKT pathways. This novel resistance mechanism involves a noncatalytic role of PLCγ1 SH2 tandem domains in the propagation of downstream signaling via SH2-containing protein tyrosine phosphatase 2 (SHP2). Accordingly, SHP2 inhibition sensitizes PLCγ1-resistant cells to cetuximab. Conclusions: Our discoveries reveal the potential of PLCγ1 as a predictive biomarker for cetuximab responses and suggest an alternative therapeutic approach to circumvent PLCγ1-mediated resistance to cetuximab in patients with RAS WT mCRC. In this way, this work contributes to the development of novel strategies in the medical management and treatment of patients with mCRC.UCIBIO - Applied Molecular Biosciences UnitDCV - Departamento de Ciências da VidaRUNCruz-Duarte, Raquelde Almeida, Cátia RebeloNegrão, MagdaFernandes, AfonsoBorralho, PaulaSobral, DanielGallego-Paez, Lina M.Machado, DanielGramaça, JoãoVílchez, JoséXavier, Ana T.Ferreira, Miguel GodinhoMiranda, Ana R.Mansinho, HélderBrito, Maria J.Pacheco, Teresa R.Abreu, CatarinaLúcia-Costa, AnaMansinho, AndréFior, RitaCosta, LuísMartins, Marta2023-03-21T22:28:11Z2022-03-152022-03-15T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article14application/pdfhttp://hdl.handle.net/10362/151024engCruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vílchez, J., Xavier, A. T., Ferreira, M. G., Miranda, A. R., Mansinho, H., Brito, M. J., Pacheco, T. R., Abreu, C., Lúcia-Costa, A., Mansinho, A., ... Martins, M. (2022). Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 28(6), 1203-1216. https://doi.org/10.1158/1078-0432.CCR-21-19921078-0432PURE: 56519855https://doi.org/10.1158/1078-0432.CCR-21-1992info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:10:25Zoai:run.unl.pt:10362/151024Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:10:25Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
title Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
spellingShingle Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Cruz-Duarte, Raquel
Oncology
Cancer Research
SDG 3 - Good Health and Well-being
title_short Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
title_full Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
title_fullStr Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
title_full_unstemmed Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
title_sort Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
author Cruz-Duarte, Raquel
author_facet Cruz-Duarte, Raquel
de Almeida, Cátia Rebelo
Negrão, Magda
Fernandes, Afonso
Borralho, Paula
Sobral, Daniel
Gallego-Paez, Lina M.
Machado, Daniel
Gramaça, João
Vílchez, José
Xavier, Ana T.
Ferreira, Miguel Godinho
Miranda, Ana R.
Mansinho, Hélder
Brito, Maria J.
Pacheco, Teresa R.
Abreu, Catarina
Lúcia-Costa, Ana
Mansinho, André
Fior, Rita
Costa, Luís
Martins, Marta
author_role author
author2 de Almeida, Cátia Rebelo
Negrão, Magda
Fernandes, Afonso
Borralho, Paula
Sobral, Daniel
Gallego-Paez, Lina M.
Machado, Daniel
Gramaça, João
Vílchez, José
Xavier, Ana T.
Ferreira, Miguel Godinho
Miranda, Ana R.
Mansinho, Hélder
Brito, Maria J.
Pacheco, Teresa R.
Abreu, Catarina
Lúcia-Costa, Ana
Mansinho, André
Fior, Rita
Costa, Luís
Martins, Marta
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv UCIBIO - Applied Molecular Biosciences Unit
DCV - Departamento de Ciências da Vida
RUN
dc.contributor.author.fl_str_mv Cruz-Duarte, Raquel
de Almeida, Cátia Rebelo
Negrão, Magda
Fernandes, Afonso
Borralho, Paula
Sobral, Daniel
Gallego-Paez, Lina M.
Machado, Daniel
Gramaça, João
Vílchez, José
Xavier, Ana T.
Ferreira, Miguel Godinho
Miranda, Ana R.
Mansinho, Hélder
Brito, Maria J.
Pacheco, Teresa R.
Abreu, Catarina
Lúcia-Costa, Ana
Mansinho, André
Fior, Rita
Costa, Luís
Martins, Marta
dc.subject.por.fl_str_mv Oncology
Cancer Research
SDG 3 - Good Health and Well-being
topic Oncology
Cancer Research
SDG 3 - Good Health and Well-being
description P. Borralho reports grants from Roche and Novartis, as well as personal fees from Bayer and AstraZeneca outside the submitted work. D. Machado reports personal fees from Amgen and Merck outside the submitted work. H. Mansinho reports grants from AstraZeneca; nonfinancial support from AstraZeneca; and personal fees from Roche, Pfizer, Pierre Fabre, Incyte, BMS, Novartis, Amgen, Servier, Merck Serono, and Grunenthal outside the submitted work. A. Mansinho reports personal fees and nonfinancial support from Merck-Serono during the conduct of the study, as well as personal fees and nonfinancial support from Amgen, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Vifor Pharma, Pfizer, Pierre Fabre, Roche, and Servier outside the submitted work. L. Costa reports grants from Merck-Serono during the conduct of the study. M. Martins reports grants from Liga Portuguesa Contra o Cancro/Terry Fox and Merck-Serono during the conduct of the study. No disclosures were reported by the other authors. We acknowledge the help of Carla Sousa and Genomed for assessing RAS mutations on tumor samples, the help of Dr. Vasco Rodrigues, and Dr. Rui Marques for their contribution at the Hospital Santa Maria Pharmacy and Champalimaud Fish Platform (C. Certal and J. Monteiro) for excellent animal care. We thank Tom Bunney and Matilda Katan for helpful advice on this project and contribution with PLCg1 plasmids. The authors thank Champalimaud Foundation and M. Godinho Ferreira for the initial support of this project. M. Martins’ research was supported by Liga Portuguesa Contra o Cancro (LPCC): Terry Fox Fundation; A. Fernandes was supported by LPCC-IMM BIOBANK; R. Fior was supported by Champalimaud Foundation and L. Costa was supported by Merck Serono. Publisher Copyright: © 2022 The Authors.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-15
2022-03-15T00:00:00Z
2023-03-21T22:28:11Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/151024
url http://hdl.handle.net/10362/151024
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vílchez, J., Xavier, A. T., Ferreira, M. G., Miranda, A. R., Mansinho, H., Brito, M. J., Pacheco, T. R., Abreu, C., Lúcia-Costa, A., Mansinho, A., ... Martins, M. (2022). Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 28(6), 1203-1216. https://doi.org/10.1158/1078-0432.CCR-21-1992
1078-0432
PURE: 56519855
https://doi.org/10.1158/1078-0432.CCR-21-1992
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 14
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545925447385088